Contemporary management of peripheral arterial disease: II. Improving walking distance and quality of life
Teresa L. Carman, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
Bernardo B. Fernandez, Jr., MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Florida,Weston, FL
Correspondence: Teresa L. Carman, MD, Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, S60, Cleveland, OH 44195; email@example.com
Dr. Carman reported that she has received honoraria for teaching and speaking from Bristol-Myers Squibb and Sanofi-Aventis.
Dr. Fernandez reported that he has received honoraria for teaching and speaking from Otsuka America Pharmaceutical.
Intermittent claudication (IC) is the classic complaint associated with peripheral arterial disease (PAD) and can significantly limit a patient's lifestyle and workplace abilities. IC is defined as reproducible pain affecting the muscles of the lower extremities that begins and increases with activity and resolves with rest. The clinical goals of management include increasing walking distance and improving quality of life. A dedicated, supervised walking program is the foundation of IC management. In addition, two drugs have been approved by the US Food and Drug Administration for the treatment of IC: cilostazol and pentoxifylline. Other agents and treatment strategies have clinical been stigated, and some promise.